Assessment of complications of combined modality radiotherapy in patients with prostate cancer using conventionally and non-conventionally fractionated doses

«Radiation and Risk», 2020, vol. 29, No. 3, pp.97-105

DOI: 10.21870/0131-3878-2020-29-3-97-105

Authors

Makarova K.S. – Radiologist. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: +7 (484) 399-31-57; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Gumenetskaya Yu.V. – Head of Dep., MD
Biryukov V.A. – Sen. Res., C. Sc., Med.
Obukhov A.A. – Sen. Res., C. Sc., Med.
Strikanova I.A. – Radiologist
Dzhabrailova S.O. – Radiologist
Kireeva T.A. – Junior Researcher
Karyakin O.B. – Head of Dep., MD, Prof. A. Tsyb MRRC, Obninsk.

A. Tsyb MRRC, Obninsk

Abstract

The study analysed the toxicity of combinatorial radiation therapy (RT) involving conventionally and non-conventionally fractionated conformal external beam radiation therapy (EBRT) in the treatment of prostate cancer (PCa). Conventionally fractionated RT induced acute grade 1 reactions of the lower urinary tracts (UT) in 66 (25.4%) patients and acute grade 2 reactions of the lower UT in three (1.2%) patients; acute grade 1 reactions of the lower gastrointestinal tract (GIT) in 35 (13.5%) and acute grade 2 reactions of the lower GIT in 5 (1.9%) patients. Late radiation-induced lower UT complications of the grade 1 were in 29 patients (11.1%) and grade 2 complications occurred in 6 patients (2.3%). Three (1.2%) patients developed the urethral stricture. Late radiation-induced lower GIT complications of the grade 1 occured in 13 patients (5%) and 8 patients (3.1%) developed complications of the grade 2. Hypofractionated RT induced acute grade 1 reactions of the lower UT in 11 (26.2%), acute grade 2 reactions of the lower UT in 2 (4.8%) and acute grade 1 reactions of the lower GIT in 10 (23.8%) patients, acute grade 2 reactions of the lower GIT occurred in 1 patient (2.38%). Late radiation-induced lower UT complications of the grade 1 occurred in 5 patients (11.9%). No late radiotherapy – related lower GIT complications were developed. The results of the study demonstrate quite acceptable level of toxicity, that allows ensuring the sustainability of well-being of prostate cancer survivors.

Key words
prostate cancer, high risk, combined modality radiotherapy, external beam radiotherapy, brachytherapy, dose escalation, hypofractionation, acute morbidity, toxicity, complications.

References

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, vol. 68, no. 6, pp. 394-424.

2. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow, Р. Hertsen MORI – branch of the NMRRC of the Ministry of Health of the Russian Federation, 2018. 250 p. (In Russian).

3. Hoskin P.J., Rojas A.M., Bownes P.J., Lowe G.J., Ostler P.J., Bryant L. Randomized trial of external beam radiotherapy alone or combined with high-dose rate brachytherapy boost for localized prostate cancer. Radiat. Oncol., 2012, vol. 103, no. 2, pp. 217-222.

4. Sathya J.R., Davis I.R., Julian J.A., Guo Q., Daya D., Dayes I.S. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J. Clin. Oncol., 2005, vol. 23, no. 6, pp. 1192-1199.

5. Vigneault E., Morton G.., Parulekar W.R., Niazi T.M., Springer C.W., Barkati M., Chung P., Koll W., Kamran A., Monreal M., Ding K., Loblaw A. Randomised phase II feasibility trial of image-guided external beam radiotherapy with or without high dose rate brachytherapy boost in men with intermediate-risk prostate cancer (CCTG PR15/NCT01982786). Clin. Oncol. (R Coll. Radiol.), 2018, vol. 30, no. 9, pp. 527-533.

6. Morris W.J., Tyldesley S., Rodda S., Halperin R., Pai H., McKenzie M. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int .J. Radiat. Oncol. Biol. Phys., 2017, vol. 98, no. 2, pp. 275-285.

7. Miralbell R., Roberts S.A., Zubizarreta E., Hendry J.H. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: a/b=1.4 (0.9-2.2) Gy. Int. J. Radiat. Oncol. Biol. Phys., 2012, vol. 82, no. 1, pp. 17-24.

8. Fowler J.F., Dasu A., Toma-Dasu I. Is the a/b ratio for prostate tumors really low and does it vary the level of risk at diagnosis? Anticancer Res., 2013, vol. 33, no. 3, pp. 1009-1011.

9. Leborgne F., Fowler J., Leborgne J.H., Mezzera J. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized pros-tate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2012, vol. 82, no. 3, pp. 1200-1207.

10. Makarova K.S., Gumenetskaya Yu.V., Biryukov V.A., Obukhov A.A., Strikanova I.A., Dzhabrailova S.O., Lepilina O.G., Borysheva N.B., Karyakin O.B., Ivanov S.A., Kaprin A.D. Combined modality radio-therapy for high-risk prostate cancer. Analysis of treatment-related complications. Sibirskii onkologicheskii zhurnal – Siberian Journal of Oncology, 2019, vol. 18, no. 2, pp. 15-21. (In Russian).

11. D’Amico A.V., Whittington R., Malkowicz S.B., Wu Y.H., Chen M., Art M., Tomaszewski J.E., Wein A. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology, 2000, vol. 55, no. 4, pp. 572-577.

12. Kaprin A.D., Galkin V.N., Zhavoronkov L.P., Ivanov V.K., Ivanov S.A., Romanko Yu.S. Synthesis of basic and applied research is the basis of obtaining high-qolity findings and translating them into clinical practice. Radiatsia I Risk – Radiation and Risk, 2017, vol. 26, no. 2, pp. 26-40. (In Russian).

13. Kaprin A.D., Mardinskiy Yu.S., Smirnov V.P., Ivanov S.A., Kostin A.A., Polikhov S.A., Reshetov I.V., Fatianova A.S., Denisenko M.V., Epatova T.V., Korenev S.V., Tereshchenko A.V., Filonenko E.V., Gafarov M.M., Romanko Yu.S. The history of radiation therapy (part I). Biomedical Photonics, 2019, vol. 8, no. 1, pp. 52-62.

14. Kaprin A.D., Smirnov V.P., Ivanov S.A., Polikhov S.A., Reshetov I.V., Fatyanova A.C., Babaeva Yu.V., Denisenko M.V., Semenova N.M., Korenev S.V., Tereshchenko A.V., Filonenko E.V., Yuzhakov V.V., Koryakin S.N., Sukhova T.E., Gafarov M.M., Ogdanskaya K.V., Romanko Yu.S. To the 115th anniver-sary of Russian radiology. The history of the development of radiation therapy: radiation diagnosis in the A. Tsyb MRRC. Biomedical Photonics, 2019, vol. 8, no. 2, pp. 47-50.

15. Kee D.L.C., Gal J., Falk A.T., Schiappa R., Chand M.E., Gautier M., Doyen J., Hannoun-Levi J.M. Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials. Cancer Treat. Rev., 2018, vol. 70, pp. 265-271.

16. Morton G.C. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J. Contemp. Brachytherapy, 2014, vol. 6, no. 3, pp. 323-330.

17. Rodda S., Tyldesley S., Morris W.J., Keyes M., Halperin R., Pai H., McKenzie M., Duncan G., Morton G., Hamm J., Murray N. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2017, vol. 98, no. 2, pp. 286-295.

18. Falk A.T., Demontoy S., Chamorey E., Chand M.E., Gautier M., Azria D., Zaki S., Chevallier D., Cham Kee D.L., Hannoun-Lévi J.M. High-dose-rate brachytherapy boost for prostate cancer: comparison of three different fractionation schemes. Brachytherapy, 2017, vol. 16, no. 5, pp. 993-999.

19. Morton G.C., Loblaw D.A., Sankreacha R., Deabreu A., Zhang L., Mamedov A., Cheung P., Keller B., Danjoux C., Szumacher E., Thomas G. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int. J. Radiat. Oncol. Biol. Phys., 2010, vol. 77, no. 3, pp. 811-817.

Full-text article (in Russian)